Standard BioTools (LAB) Expected to Announce Quarterly Earnings on Wednesday

Standard BioTools (NASDAQ:LAB) is anticipated to issue its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $18.00 million for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

Standard BioTools Trading Up 3.1%

Shares of NASDAQ:LAB opened at $1.32 on Wednesday. The company has a market cap of $504.23 million, a price-to-earnings ratio of -4.13 and a beta of 1.31. The company has a 50-day moving average price of $1.30 and a 200-day moving average price of $1.22. Standard BioTools has a 12 month low of $0.92 and a 12 month high of $2.32.

Analyst Ratings Changes

LAB has been the subject of several recent analyst reports. Cowen downgraded shares of Standard BioTools from a “buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Wall Street Zen raised shares of Standard BioTools from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Standard BioTools in a research note on Wednesday, October 8th. Finally, TD Cowen downgraded shares of Standard BioTools from a “buy” rating to a “hold” rating and set a $1.55 price target for the company. in a research note on Wednesday, August 13th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Standard BioTools currently has an average rating of “Reduce” and an average price target of $1.55.

Insider Transactions at Standard BioTools

In related news, Director Casdin Partners Master Fund, L purchased 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was bought at an average cost of $1.27 per share, with a total value of $317,500.00. Following the completion of the purchase, the director directly owned 60,525,000 shares in the company, valued at approximately $76,866,750. This represents a 0.41% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have bought 1,233,220 shares of company stock valued at $1,546,446 over the last ninety days. 23.16% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Standard BioTools

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its holdings in Standard BioTools by 50.3% in the second quarter. BNP Paribas Financial Markets now owns 29,826 shares of the company’s stock worth $36,000 after purchasing an additional 9,986 shares during the period. Jane Street Group LLC purchased a new stake in Standard BioTools in the second quarter worth about $43,000. Cerity Partners LLC grew its holdings in Standard BioTools by 70.2% in the second quarter. Cerity Partners LLC now owns 37,501 shares of the company’s stock worth $45,000 after purchasing an additional 15,470 shares during the period. Prudential Financial Inc. grew its holdings in Standard BioTools by 72.7% in the second quarter. Prudential Financial Inc. now owns 39,307 shares of the company’s stock worth $47,000 after purchasing an additional 16,541 shares during the period. Finally, Creative Planning grew its holdings in Standard BioTools by 56.6% in the second quarter. Creative Planning now owns 61,102 shares of the company’s stock worth $73,000 after purchasing an additional 22,082 shares during the period. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.